Ghrelin activation and neuropeptide Y elevation in response to medium chain triglyceride administration in anorexia nervosa patients  by Kawai, Keisuke et al.
lable at ScienceDirect
Clinical Nutrition ESPEN xxx (2016) 1e5Contents lists avaiClinical Nutrition ESPEN
journal homepage: http : / /www.cl in icalnutr i t ionespen.comOriginal articleGhrelin activation and neuropeptide Y elevation in response to
medium chain triglyceride administration in anorexia nervosa
patients
Keisuke Kawai a, b, *, Megumi Nakashima b, Masayasu Kojima c, Sakino Yamashita b,
Shu Takakura b, Miki Shimizu b, Chiharu Kubo d, Nobuyuki Sudo b
a Department of Psychosomatic Medicine, Kohnodai Hospital National Center for Global Health Medicine 1-7-1, Kohnodai, Ichikawa City, Chiba, 272-8516,
Japan
b Department of Psychosomatic Medicine, Graduate School of Medical Sciences Kyushu University, Fukuoka, 812-8582, Japan
c Institute of Life Science, Kurume University, Kurume, 830-0864, Japan
d Kyushu University, Fukuoka, 819-0315, Japana r t i c l e i n f o
Article history:
Received 22 September 2016
Accepted 5 October 2016
Keywords:
Anorexia nervosa
Ghrelin
Activation
Medium-chain triglycerides
Neuropeptide Y* Corresponding author. Department of Psychos
Hospital National Center for Global Health Medicine 1
Chiba, 272-8516, Japan.
E-mail address: kawai@cephal.med.kyushu-u.ac.jp
http://dx.doi.org/10.1016/j.clnesp.2016.10.001
2405-4577/© 2016 The Authors. Published by Elsevier
NC-ND license (http://creativecommons.org/licenses/b
Please cite this article in press as: Kawai K,
administration in anorexia nervosa patientss u m m a r y
Background & aims: Ghrelin, a peptide found in the stomach, increases appetite and fat-free mass while
suppressing energy expenditure. Ghrelin requires modiﬁcation by medium-chain triglycerides (MCTs) to
exert its physiological effects. In this study, we investigated ghrelin activation and the resulting physi-
ological changes following MCT administration.
Methods: Thirty participants were selected from among inpatients diagnosed with anorexia nervosa
(AN). The patients were randomly divided into three groups by the MCT content of their nutritional
supplement: (1) ‘MCT high’ (>6 g/day), (2) ‘MCT moderate’ (1e6 g/day), and (3) ‘MCT low’ (<1 g/day).
Physical factors such as body weight and composition, as well as levels of nutrition-related serum factors
such as acylated (active form) and desacyl (inactive form) ghrelin, leptin, growth hormone, insulin-like
growth factor, and neuropeptide Y (NPY) were measured at weeks 0, 2, 4, and 6 of the treatment
protocol.
Results: Signiﬁcantly higher ghrelin activation was found in the ‘MCT high’ than in the ‘MCT low’ group
(P < 0.05). The amount of consumed MCT had a curvilinear relationship with the active ghrelin level
(P ¼ 0.00). NPY levels in the ‘MCT high’ group were signiﬁcantly more elevated than in the ‘MCT low’
group (P < 0.05). MCT administration did not signiﬁcantly affect the remaining factors.
Conclusions: This study clearly demonstrated that MCT activates ghrelin and increases NPY, suggesting
that nutritional supplementation with MCT may be effective for the treatment of AN patients in an
emaciated state.
© 2016 The Authors. Published by Elsevier Ltd on behalf of European Society for Clinical Nutrition and
Metabolism. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Ghrelin is an endogenous ligand of the growth hormone
secretagogue receptor family [1]. This peptide originates in the
stomach and increases appetite through the stimulation of neuro-
peptide Y (NPY) neurons in the arcuate nucleus, leading to theomatic Medicine, Kohnodai
-7-1, Kohnodai, Ichikawa City,
(K. Kawai).
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, Clinical Nutrition ESPEN (20augmentation of fat-free mass (FFM) and suppression of energy
expenditure [2e5]. Ghrelin peptides exist mainly in two forms:
active (acylated ghrelin) and inactive (desacyl ghrelin).
The side chain of the third serine residue of ghrelin must be
modiﬁed by medium-chain triglycerides (MCTs) to exert its physi-
ological effects [1]. MCT is a saturated fatty acid in which the
aliphatic tail comprises of 6e12 carbon atoms; it is found in milk,
coconut oil (15%), and Makuton Oil® (85%).
Anorexia nervosa (AN) is an eating disorder that results in
extreme weight loss due to an intense fear of gaining weight,
without the presence of any basal organic disease. Total ghrelinor Clinical Nutrition and Metabolism. This is an open access article under the CC BY-
neuropeptide Y elevation in response to medium chain triglyceride
16), http://dx.doi.org/10.1016/j.clnesp.2016.10.001
Fig. 1. Experimental Protocol. The patients were randomly divided into three groups
by the MCT content of their nutritional supplement. The factors related to ghrelin
activation were measured at 2, 4, and 6 weeks after the start of the protocol. MCT:
medium chain triglyceride.
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because of refraction to the inhibitory inﬂuence of food intake [6].
Moreover, most of the ghrelin in untreated AN patients is inactive
(desacyl) ghrelin [7]; this phenomenon reﬂects a chronic starvation
state.
The activation of ghrelin might be effective for treating diseases
that result in emaciation. In a pilot study, ghrelin infusion into AN
patients resulted in increased daily energy intake compared to the
pre-treatment period; there were no serious adverse events [8].
However, ghrelin products are unstable and expensive to produce;
therefore, we explored the notion of activating ghrelin via MCT.
Previous data showed that MCT ingestion increased plasma ghrelin
concentrations in lactating dairy cows [9]. Moreover, ingestion of
MCTs increased stomach acylated ghrelin levels in mice, although
the amount of total ghrelin remained unchanged [10]. In this study,
we investigated ghrelin activation in AN patients receiving nutri-
tional treatment with high MCT supplementation (PemPal®).
Additionally, we investigated factors that may be involved in
ghrelin activation, such as growth hormone (GH) levels, NPY levels,
and body composition.
2. Methods
2.1. Participants
The study group was composed of 30 new AN inpatients who
were treated at the Department of Psychosomatic Medicine of
Kyushu University Hospital between 2012 and 2013. A diagnosis of
AN was based on the eating disorders section of the Structured
Clinical Interview for DSM (Diagnostic and Statistical Manual)-IV
Axis I Disorders [11]. The enrollment criteria were as follows: 1)
Admission to the hospital for enrollment in our “Cognitive Behav-
ioral Therapy” treatment program, and 2) sustained enrollment in
the treatment program for at least four months.
2.2. Nutrition program
Behavioral observation was performed during the ﬁrst two
weeks of admission. During this period, electrolyte abnormalities,
including dehydration or edema, were almost normalized. After the
observation period, the cognitive behavior treatment program
commenced and continued until a patient achieved the target body
weight, which was set at 60e80% of the standard body weight
based on consultation between the patient and the medical staff;
data were collected during this period [12]. After observation, all
participating patients underwent combined oral and nasal tube
feeding. Calorie consumption started at 30e40 kcal/kg/day and
increased by 200 kcal/day every two weeks; patients pledged to
consume each meal in its entirety. Fig. 1 shows the experimental
protocol. The calories administered by nasogastric tube feeding
were gradually shifted to oral intake in the latter half of the pro-
gram. Self-induced vomiting and over-exercising were restricted as
much as possible; outdoor activities, which required exit passes
from the premises, were supervised by the staff.
2.3. Experimental protocol
Anorexia nervosa patients were randomly assigned to nutri-
tional supplementation groups that included rich amounts of MCT
(2.25 g/100 mL) (PemPal®: Nestle Health Science); medium
amounts (0.84 g/100 mL) (Isocal RTU®, Nestle Health Science), or
none (0 g/125 mL) (Ensure Liquid®). For analysis, the patients were
divided into the following categories: ‘MCT-high’ (>6 g/day), ‘MCT-
moderate’ (1e6 g/day), and ‘MCT-low’ (0 g/day) according to the
average daily amount of MCT included in their nasal feedingPlease cite this article in press as: Kawai K, et al., Ghrelin activation and
administration in anorexia nervosa patients, Clinical Nutrition ESPEN (20nutritional supplements. The last category was referred to as ‘MCT-
low’ to account for the small quantities contained in regular food
(<0.3 g/day).
Body mass index (BMI), heart rate, body temperature, systolic
and diastolic blood pressure, energy intake, appetite, and serum
nutrition-related factors (active ghrelin, inactive ghrelin, growth
hormone [GH], insulin-like growth factor-1 [IGF-1], and NPY) were
measured at 0, 2, 4, and 6 weeks after the start of the protocol;
these factors were analyzed and compared among each of the MCT
intake categories. Furthermore, the correlation of activated ghrelin
and total MCT was assessed between weeks 2 and 6.2.4. Anthropometry
Food intake was assessed by visual estimation of the patients'
main and side dishes separately by two skilled nurses. Subjects'
heights were measured without shoes using a stadiometer to the
nearest 0.1 cm on the day of admission. BMI was calculated as the
ratio of body weight (kg) to height (m) squared.
Blood pressure, pulse, and temperature were measured every
morning at 6:00. Weight, FFM, and bone mineral density (BMD)
were determined for the whole body using dual-energy X-ray ab-
sorptiometry with a HOLOGIC QDR-1000 densitometer (2000 to
March 2002) or a HOLOGIC QDR-4500 densitometer (April 2002 to
2006) (Hologic, Inc. Waltham, MA, USA). Both FFM and BMD were
measured one week and three-to-four months after admission. All
measurements were performed by an experienced technician.2.5. Laboratory analysis methods
Acylated ghrelin levels were measured using the Active Ghrelin
ELISA Kit (Mitsubishi Kagaku Iatron Tokyo, Japan) with interassay
and intraassay coefﬁcients of variation less than 8.3% and 8.1%,
respectively. Desacyl ghrelin levels were measured using the
Desacyl-Ghrelin ELISA Kit (Mitsubishi Kagaku Iatron, Tokyo, Japan)
with interassay and intraassay coefﬁcients of variation less than
10.3% and 12.7%, respectively. Serum IGF-1 level was measured
using an immunoradiometric assay kit (TFB Inc., Tokyo, Japan) with
an interassay coefﬁcient of variation of 1.1e2.4% and a sensitivity of
10 ng/mL. SerumGH level wasmeasured using a chemiluminescent
enzyme immunoassay (BeckmaneCoulter Inc., CA, USA) with an
interassay coefﬁcient of variation of 3.7e8.44% and a sensitivity of
0.003 ng/mL. Serum NPY levels were measured via ELISA (EMDneuropeptide Y elevation in response to medium chain triglyceride
16), http://dx.doi.org/10.1016/j.clnesp.2016.10.001
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efﬁcients of variation less than 3.84% and 9.40%, respectively.2.6. Statistical analysis
All analyses were performed using SPSS for Windows version
14.0J. Results are presented as means ± standard deviation. Com-
parisons among groups at weeks 0, 2, 4, and 6 were performed
using one-way ANOVA, after which a post-hoc test was used for
group comparisons. NPY was compared in terms of the rate of in-
crease from week 0 because of the large difference in absolute
values between the ﬁrst and second assays at that time point.
Pearson's single correlation analysis was performed to compare the
amount of ingested MCT to activated ghrelin levels inweeks 2e4 of
the treatment protocol. The study was approved by the Ethics
Committee of Kyushu University (No. 22-56). All participants pro-
vided written informed consent.3. Results
3.1. Clinical characteristics
There were no signiﬁcant differences in the clinical character-
istics (BMI, age, duration of disease, heart rate, body temperature,
and systolic and diastolic blood pressure) of the three groups two
weeks after admission (Table 1).3.2. Basal hormone level
There were no signiﬁcant differences between active ghrelin,
desacyl ghrelin, GH, IGF-1, and NPY levels among the three groups
(Table 2).3.3. Clinical course after MCT administration
Fig. 2 shows that the daily amounts of MCT administered to the
‘MCT-high’ group were signiﬁcantly higher than those adminis-
tered to the ‘MCT-low’ group at weeks 2, 4, and 6 (7.07 ± 2.74 vs.
0.55 ± 1.17, P ¼ 0.03; 9.00 ± 2.62 vs. 2.49 ± 2.49, P ¼ 0.00; and
6.48 ± 4.87 vs. 0.11 ± 0.36, P¼ 0.01; respectively). The average daily
amount of MCT administered to the ‘MCT-moderate’ group was
higher than that administered to the ‘MCT-low’ group at weeks 2, 4,
and 6, but without signiﬁcance. No signiﬁcant differences in BMI or
energy intake were found among the three groups at 0, 2, 4, or 6
weeks after MCT administration. Moreover, differences in heart
rate, body temperature, systolic blood pressure, and diastolic blood
pressure between the groups were not signiﬁcant (data not shown).Table 1
Clinical characteristics of anorexia nervosa patients by MCT consumption.
‘MCT high’ group N ¼ 10 ‘M
BMI at admission (kg/m2) 13.0 ± 1.4 12
Duration (years) 7.1 ± 9.9 2.
Age (years) 26.4 ± 10.8 28
Subtype (AN-R/AN-BP) 6/4 5/
Length of hospitalization (days) 171.6 ± 63.6 14
Body temperature (C) 36.4 ± 0.19 36
Heart rate 63.4 ± 13.3 69
Blood pressure (systolic/digastric) 85.7 ± 11.7/57.1 ± 9.5 83
Values are expressed as mean ± standard deviation or number of patients. *Unpaired St
MCT: medium-chain triglyceride, AN-R: anorexia nervosa, restricting type, AB-BP: anore
Please cite this article in press as: Kawai K, et al., Ghrelin activation and
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Fig. 3 shows that acylated ghrelin was signiﬁcantly higher in the
‘MCT high’ group than in the ‘MCT-low’ group at weeks 2 and 4
(P< 0.05). No signiﬁcant differences in desacyl ghrelin levels during
MCT administration were found among the three groups. An MCT
dose of 6 g/day was required to produce an effect, and a positive
correlation was found between the amount of MCT administered
and activated ghrelin levels between weeks 2e6 of the treatment
protocol (r ¼ 0.44, P ¼ 0.00; Fig. 4).
3.5. Change of NPY and other somatic factors after MCT
administration
The rate of NPY increase was signiﬁcantly higher in the ‘MCT
high’ group than in the ‘MCT-low’ group at week 4 (2.88 ± 0.83 vs.
1.28 ± 0.13, respectively; P < 0.05; Fig. 3). GH and IGF-1 were not
signiﬁcantly different between the three groups (data not shown).
The incremental changes in FFM and BMC from admission to
discharge were not signiﬁcant between the three groups (FFM in-
crements: ‘MCT-low’: 3546 ± 606.4, ‘MCT-moderate’:
4283.0 ± 724.8, ‘MCT-high’: 4546.7 ± 707.8 g; BMD increments:
‘MCT-low’: 1.25 ± 0.54; ‘MCT-moderate’: 0.76 ± 0.54, and ‘MCT-
high’: 1.65 ± 0.77).
4. Discussion
MCT nutritional supplementation signiﬁcantly increased acyl-
ated ghrelin in AN patients in a dose-dependent manner. Further-
more, NPY, a peptide that functions downstream of ghrelin, was
elevated after MCT administration [1,5]. Thus, MCT nutritional
supplementation may be effective for improving the nutritional
status of AN patients who are in a prolonged state of malnutrition
and in whom desacyl ghrelin levels are elevated.
Normal fat intake in healthy persons is approximately 50 g/day,
with the quantity of MCT estimated to be approximately 0.3 g/day.
However, 20 times that amount (i.e., 6 g/day) is necessary to pro-
duce a biological effect. MCT is hydrolyzed in the intestinal tract by
lipase and carried to the liver directly through the portal vein. It is
metabolized faster than long-chain fatty acids during parenteral
nutrition [13]. As such, MCT might have contributed to the man-
agement of energy metabolism, but not to the activation of ghrelin,
in the early days of this treatment protocol. No signiﬁcant differ-
ence was found in desacyl ghrelin levels, possibly because its blood
levels are approximately 10-fold higher than those of activated
ghrelin [8]. This suggests that the quantity of desacyl ghrelin is not
affected by MCT administration but by the secretion capacity of
ghrelin itself.
The effects of ghrelin extend beyond appetite improvement, and
include the enhancement of cardiac activity, amelioration of cancerCT moderate’ group N ¼ 10 ‘MCT low’ group N ¼ 10 P*
.6 ± 1.6 12.4 ± 2.4 n.s.
2 ± 2.0 5.3 ± 8.6 n.s.
.5 ± 12.1 26.2 ± 13.4 n.s.
5 7/3 n.s
1.1 ± 60.3 148.8 ± 72.2 n.s.
.4 ± 0.34 36.55 ± 0.34 n.s.
± 17.3 64.9 ± 10.9 n.s
.3 ± 8.7/50.6 ± 9.9 86.7 ± 10.5/54.6 ± 9.3 n.s.
udent's t test.
xia nervosa, binge-purging type, BMI: body mass index, n.s.: not signiﬁcant.
neuropeptide Y elevation in response to medium chain triglyceride
16), http://dx.doi.org/10.1016/j.clnesp.2016.10.001
Table 2
Clinical characteristics of anorexia nervosa patients by MCT consumption.
‘MCT high’ group N ¼ 10 ‘MCT moderate’ group N ¼ 10 ‘MCT low’ group N ¼ 10 P*
Acylated ghrelin (fmol/mL) 23.6 ± 15.9 28.5 ± 21.3 24.6 ± 12.6 n.s.
Desacyl ghrelin (fmol/mL) 210.4 ± 129.0 223.8 ± 176.0 269.2 ± 163.2 n.s.
GH (ng/mL) 2.63 ± 1.78 8.73 ± 15.4 10.12 ± 25.1 n.s.
IGF-1 (ng/mL) 180.9 ± 75.9 180.4 ± 108.4 193.9 ± 119.1 n.s
Values are expressed as mean ± standard deviation. *Unpaired Student's t test.
MCT: medium-chain triglyceride, GH: growth hormone, IGF-1: insulin-like growth factor-1.
Fig. 2. Change in daily dose of MCT, energy intake, and BMI after the start of the protocol. BMI: Body mass index, MCT: medium-chain triglyceride.
Fig. 3. Change of acylated ghrelin, desacyl ghrelin, and NPY concentration after MCT administration. MCT: medium-chain triglyceride, NPY: neuropeptide Y.
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preservation of muscle or lean body mass [3,4,14e16]. The cardio-
vascular effects of ghrelin include improvement of left ventricular
contractility and cardiac output, as well as the reduction of arterial
pressure and systemic vascular resistance in healthy subjects [3,15].
Additionally, ghrelin increases osteoblastic activity in cell cultures,
suggesting bone anabolic effects [16]. In our study, other factors
such as body temperature, blood pressure, heart rate, BMI, energy
intake, BMD, and GH and IGF-1 levels were not signiﬁcantly
changed among the three groups based on the amount of MCT
administration. While the average incremental increase in FFM
correlated with the amount of MCT, the change was also not
signiﬁcant.
Our ﬁndings may be affected by (1) the food intake during MCT
administration being determined by the treatment protocol,
particularly as meal quantity increases were incremental, and (2)
the period of MCT administration not being long enough to changePlease cite this article in press as: Kawai K, et al., Ghrelin activation and
administration in anorexia nervosa patients, Clinical Nutrition ESPEN (20the body composition. In fact, the body composition was measured
for approximately ﬁve months before and after hospitalization,
while MCT was administered for two to three weeks during this
period. Therefore, it is possible that the recovery of nutritional
status and volume of exercise were insufﬁcient. Of note, it has been
reported that GH responses to ghrelin infusion were blunted in AN
patients by the effect of prolonged exposure to hyperghrelinemia or
the hyperactivity of the hypothalamo-pituitary-adrenal axis [17].
Hence, the clinical effects of the administration of 6 g/day of MCT
may only manifest after a prolonged period in such cases. Future
studies ought to focus on the amount of MCT and the length of the
period of administration necessary to provide the greatest beneﬁt
to the patient.
An important ﬁnding of this study was that ghrelin and NPY
increased owing to MCT administration; the level of increase was
consistent with that observed following conventional administra-
tion of the traditional Japanese medicine Rikkunshito, which isneuropeptide Y elevation in response to medium chain triglyceride
16), http://dx.doi.org/10.1016/j.clnesp.2016.10.001
Fig. 4. The relationship between MCT amount and acylated ghrelin levels at weeks
2e6 of the treatment protocol. MCT: medium-chain triglyceride.
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[18]. It has been reported that Rikkunshito increases the plasma
level of ghrelin in healthy humans and normal mice [1]. Recently, a
ﬂavonoid that is a component of Rikkunshito was shown to reverse
cisplatin-induced suppression of plasma acylated ghrelin levels and
cause increased food intake in rats; this was mediated by 5-HT2B/
2C receptors [19]. The standard Rikkunshito dosage is 7.5 g/day, at
which the quantity of blood activated ghrelin increases approxi-
mately 1.5-fold. An equivalent effect was observed when adminis-
tering 6 g/day of MCT in this study. Importantly, the cost per day for
MCT (50 Japanese yen) is cheaper than that of herbal medicinal
products (150 Japanese yen).
A limitation of our study was that the amount of calories
included in the patients' daily diet was ﬁxed by our treatment
protocol; hence, there was not much latitude for measuring any
change in calorie intake. Another limitation was that subjective
appetite was not evaluated, even though the intervention of psy-
chological factors peculiar to eating disorders, including the
extreme desire for thinness, has a strong effect on clinical sequelae
[2,8]. In such cases, any increases in the levels of ghrelin may be
insufﬁcient to inﬂuence the human body.
In a previously described experimental rat model, ghrelin deﬁ-
nitely increased bone mineral density [3,16]. MCT could therefore
be a valuable treatment option for patients who suffer from
malnutrition, such as the elderly and patients with cancer or res-
piratory failure. We also have high expectations for the successful
clinical application of MCT treatment in patients with cachexia or
chronic respiratory deﬁciency.
In conclusion, MCT nutritional supplementation increased the
amount of activated ghrelin and NPY in AN patients. Our data
suggest thatMCT treatmentmay constitute a promising strategy for
undernourished patients.Funding sources
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